

## **Supplemental tables and figures**

### List of Supplemental Tables

Table S1: Baseline demographic and disease characteristics of all participants.

Table S2: Disease response summary

Table S3: IWG2023 classifications

Table S4: Delayed treatment cycles

Table S5: Serious adverse events and adverse events

Table S6: Myeloid gene panel

Table S7: Variant allele frequencies at diagnosis, C6D29, C12D29, and Progression

**Table S1: Baseline demographic and disease characteristics of all participants.**

\* Cytopenias defined as haemoglobin < 100 g/L, absolute neutrophil count < 1.8 x 10<sup>9</sup>/L, platelet count < 100 x 10<sup>9</sup>/L.

<b>Characteristic</b>	<b>MDS n= 31 (77.5%)</b>	<b>AML n= 6 (15%)</b>	<b>CMML n= 3 (7.5%)</b>
<b>Age (yrs) median (min,max)</b>	76.2 (65.9, 87.4)	77.3 (74.9, 83.8)	73 (73, 82.1)
<b>Gender n(%)</b>			
<b>Female</b>	9 (22.5)	2 (5)	1 (2.5)
<b>Male</b>	22 (55)	4 (10)	2 (5)
<b>ECOG PS n (%)</b>			
0	17 (42.5)	1 (2.5)	1 (2.5)
1	10 (25)	4 (10)	2 (5)
2	4 (10)	1 (2.5)	0
<b>BMA blast count % median (min,max)</b>	12 (1, 20)	22.5 (20, 30)	11 (10, 18)
<b>IPSS risk group n= (%)</b>			
Low	0		
Int-1	0		
Int-2 (1.5-2)	22 (71)		
High risk (≥2.5)	9 (29)		
<b>IPSS-R risk group n= (%)</b>			
Very low	0		
Low	1 (3)		
Intermediate	3 (10)		
High	15 (48)		
Very high	12 (39)		
<b>Karyotype n= (%)</b>			
Normal, Y-, 5q-, 20q-	13 (42)		
Abnormal chromosome 7 or 3 or more abnormalities	13 (42)		
All other cytogenic abnormalities	5 (16)		
<b>Cytopenia of 2 or 3 cell types* n= (%)</b>			
No cytopenia or cytopenia of 1 cell type	6 (19)		
Cytopenia of 2 or 3 cell types	25 (81)		
<b>ELN risk stratification n= (%)</b>			
Favourable		1 (17)	
Intermediate		3 (50)	
Adverse		2 (33)	
<b>WHO subtype</b>			
CMML-1 blasts			0 (0)
CMML-2 blasts			3 (100)
<b>Hematology</b>			
Hemoglobin median (min,max) g/L	96 (73, 132)	88 (79, 121)	106 (95, 124)
ANC median (min,max) x 10 <sup>9</sup> /L	0.8 (0.2, 26.7)	1.7 (0.1, 6.7)	8.9 (4.3, 50.3)
WCC median (min,max) x 10 <sup>9</sup> /L	2.3 (0.9, 74.1)	3.4 (0.7, 23)	14.8 (8.5, 81.1)
Platelet median (min,max) x 10 <sup>9</sup> /L	61 (9, 438)	43.5 (28, 320)	40 (23, 99)

**Table S2: Disease response summary.** Shown are the number of participants achieving the indicated IWG response at end of injected phase (C6) and end of oral phase (C12) and a quantification of best response for each participant who completed the injection phase. Disease progression reported at timepoints other than IWG assessment at C6 and C12 is detailed in Figure 1C.

	<b>IWG response</b>	<b>C6D29</b>	<b>C12D29</b>	<b>Best response</b>
Responder	Complete remission (CR)	7	2	8
	Partial remission (PR)	0	0	0
	Marrow CR	3	4	4
	Hematological improvement (HI)	6	1	6
Non-responder	Stable disease (SD)	5	2	3
	Failure	1	0	1
	Relapse after CR or PR	0	1	0
	Disease progression	2	1	2
Totals		24	11	24

**Table S3: IWG2023 classifications.** Compared to IWG2006, classification of one patient (\*; P10) changed from non-responder to responder at C12D29.

Patient	Injection phase		Oral phase	
	IWG 2023	Response	IWG 2023	Response
P01	CRbi	Responder	CRh	Responder
P02	No response	Non-responder		
P03	CR	Responder	CR	Responder
P04	CR	Responder	PD	Non-responder
P05	CR	Responder	Disease relapse	Non-responder
P06	HI-P	Responder	No response	Non-responder
P07	No response	Non-responder	CRuni	Responder
P08	No response	Non-responder		
P09	No response	Non-responder	CRh	Responder
P10	HI-E	Responder	HI	Responder *
P11	CRbi	Responder	CR	Responder
P12	CR	Responder	CR	Responder
P13	HI	Responder	HI	Responder
P14	CR	Responder		
P15	HI-P	Responder		
P16	No response	Non-responder		
P17	CR	Responder		
P18	CR	Responder		
P19	HI	Responder		
P20	HI-E	Responder		
P21	CRbi	Responder		
P22	No response	Non-responder		
P24	No response	Non-responder		
P25	No response	Non-responder		

**Table S4: Delayed treatment cycles.** Shown are duration and reasons for cycle delays of greater than 3 days.

Participant	Cycle	Duration (days)	Reason
P01	7	7	Participant holidays/work
	8	7	Haematological toxicity
	9	14	Haematological toxicity
	10	7	Haematological toxicity
	11	7	Haematological toxicity
	12	7	Haematological toxicity
P02	4	21	Non-haematological toxicity
	6	28	SAE/AE followed by suspected disease progression
P03	7	7	Unable to obtain PD bloods
P04	1	14	SAE
P06	2	11	SAE in previous cycle
P07	9	11	Participant holidays/work
P08	4	28	Participant holidays/work
	7	21	Haematological toxicity
	10	10	Haematological toxicity
P09	11	7	SAE
P10	2	7	Haematological toxicity
P14	5	14	Xmas closure
	10	14	Suspected disease progression
P18	7	4	Haematological toxicity
P19	2	7	Brief hospitalisation for Colitis (Grade 2)
P23	3	21	Non-haematological toxicity
	5	14	Haematological toxicity
P24	3	7	SAE
	4	8	Haematological toxicity
	5	6	Chest pain - hospitalisation
P32	2	7	Non-haematological toxicity

**Table S5: (A-B) Serious adverse events and adverse events.**

**(A) Serious adverse events (SAE).** Table indicates the number of participants experiencing each SAE in each treatment cycle.

SAE event	Cycle number - injection phase							Cycle number - oral phase						
	1	2	3	4	5	6	Total	7	8	9	10	11	12	Total
febrile neutropaenia	3	3	4	2			12					1		1
anaemia	1	1	1				3			1	1			2
pyrexia				1		2	3	1						1
thrombocytopenia	2			1			3	1						1
sepsis			1		1		2							0
mouth haemorrhage		1	1				2							0
musculoskeletal pain			1	1			2							0
upper respiratory tract infection	1		1				2							0
rectal haemorrhage				1			1			1			1	2
diarrhoea				1			1				1			1
neutropenia				1			1				1			1
abdominal pain	1						1							0
acute kidney injury			1				1							0
acute pulmonary oedema				1			1							0
anal fissure	1						1							0
cellulitis	1						1							0
cerebrovascular accident	1						1							0
coronary artery disease				1			1							0
haemolytic anaemia	1						1							0
haemorrhoid infection			1				1							0
hepatic failure			1				1							0
hyponatremia		1					1							0
intra-abdominal haematoma	1						1							0
jejunal perforation				1			1							0
joint swelling			1				1							0
nasal vestibulitis			1				1							0
oedema peripheral	1						1							0
pain		1					1							0
parotid gland enlargement				1			1							0
pericardial effusion			1				1							0

pneumonia			1			1							0
septic shock	1					1							0
skin infection		1				1							0
soft tissue infection					1	1							0
transitional cell carcinoma		1				1							0
upper gastrointestinal haemorrhage				1		1							0
urinary tract infection					1	1							0
uterine cancer						1	1						0
myocardial infarction						0			2				2
cardiac failure acute						0						1	1
escherichia sepsis						0				1			1
lung infection						0						1	1
prostate infection						0			1				1

**(B) Adverse events: Grade 4 haematological and Grade 3 non-haematological adverse events (AE).** Table indicates the number of participants experiencing each AE in each treatment cycle.

AE grade	AE event	Cycle number - injection phase							Cycle number - oral phase						
		1	2	3	4	5	6	Uniq PIDs	7	8	9	10	11	12	Uniq PIDs
HAEM AE Grade 4	neutropenia	7	9	8	6	4	4	16	5	3	4	4	3	3	12
	thrombocytopenia	11	10	6	4	4	3	15	3	1	2	3	2	2	9
	white blood cell count decreased	1	2	2	2	0	0	3	0	0	0	1	0	1	2
Non HAEM AE Grade 3	abdominal pain								0	0	1	0	0	0	1
	anxiety								0	0	1	0	0	0	1
	ascites	0	1	0	0	0	0	1							
	blood creatinine increased	0	0	1	0	0	0	1							
	chronic obstructive pulmonary disease	0	0	0	1	1	0	1							
	diarrhoea								1	1	1	1	0	0	2
	epistaxis	0	1	0	0	0	0	1							
	haematuria								0	1	0	0	0	0	1
	hyperbilirubinaemia	0	0	2	0	0	0	2							
	hyperglycaemia	0	0	0	1	0	0	1							
	hypokalaemia	0	0	0	1	0	0	1							
	hyponatremia	0	0	1	0	0	0	1							
	nausea								1	2	0	1	0	0	3
	sebaceous carcinoma	0	0	0	0	1	0	1							
	upper gastrointestinal haemorrhage	0	0	0	0	1	0	1							
urinary tract infection	0	1	0	0	0	0	1								
vomiting								0	0	0	1	0	0	1	
sepsis								0	0	1	0	0	0	1	
<b>Total unique PIDs</b>		<b>16</b>	<b>19</b>	<b>15</b>	<b>9</b>	<b>8</b>	<b>7</b>	<b>28</b>	<b>8</b>	<b>6</b>	<b>7</b>	<b>7</b>	<b>3</b>	<b>4</b>	<b>19</b>



**Table S6: Myeloid gene panel**

Gene Names		
<i>ABCB1</i>	<i>GATA1</i>	<i>PTEN</i>
<i>ABCG2</i>	<i>GATA2</i>	<i>PTPN11</i>
<i>ABL1</i>	<i>GATA3</i>	<i>PTPRT</i>
<i>ALAS2</i>	<i>GNAS</i>	<i>RAD21</i>
<i>ANKRD26</i>	<i>GNB1</i>	<i>RAF1</i>
<i>ASXL1</i>	<i>HIST1H1E</i>	<i>RPL11</i>
<i>ATM</i>	<i>HRAS</i>	<i>RPL35A</i>
<i>ATR</i>	<i>IDH1</i>	<i>RPL5</i>
<i>AXL</i>	<i>IDH2</i>	<i>RTEL1</i>
<i>BCOR</i>	<i>IKZF1</i>	<i>RUNX1</i>
<i>BCORL1</i>	<i>IL7R</i>	<i>SAMD9</i>
<i>BRAF</i>	<i>JAK1</i>	<i>SAMD9L</i>
<i>BRCA1</i>	<i>JAK2</i>	<i>SAMHD1</i>
<i>BRCA2</i>	<i>JAK3</i>	<i>SBDS</i>
<i>BRD4</i>	<i>KDM6A</i>	<i>SETBP1</i>
<i>CALR</i>	<i>KIT</i>	<i>SF1</i>
<i>CBL</i>	<i>KMT2A</i>	<i>SF3A1</i>
<i>CCND2</i>	<i>KRAS</i>	<i>SF3B1</i>
<i>CDA</i>	<i>LIG4</i>	<i>SMARCA2</i>
<i>CDKN2A</i>	<i>MECOM</i>	<i>SMC1A</i>
<i>CEBPA</i>	<i>MED12</i>	<i>SMC3</i>
<i>CSF1R</i>	<i>MPL</i>	<i>SRP72</i>
<i>CSF3R</i>	<i>MYD88</i>	<i>SRSF2</i>
<i>CTC1</i>	<i>MYSM1</i>	<i>STAG2</i>
<i>DAXX</i>	<i>NOTCH1</i>	<i>STIM1</i>
<i>DCK</i>	<i>NPM1</i>	<i>SYK</i>
<i>DCLK1</i>	<i>NRAS</i>	<i>TERC</i>
<i>DDX41</i>	<i>PARN</i>	<i>TERT</i>
<i>DIS3</i>	<i>PDGFRA</i>	<i>TET2</i>
<i>DKC1</i>	<i>PHF6</i>	<i>TINF2</i>
<i>DNAJC21</i>	<i>PIK3CD</i>	<i>TP53</i>
<i>DNMT3A</i>	<i>PIK3CG</i>	<i>TYK2</i>
<i>ERCC6L2</i>	<i>PLCG2</i>	<i>U2AF1</i>
<i>ETV6</i>	<i>PPM1D</i>	<i>U2AF2</i>
<i>EZH2</i>	<i>PRF1</i>	<i>WAC</i>
<i>FBXW7</i>	<i>PRKCB</i>	<i>WT1</i>
<i>FLT3</i>	<i>PRKD3</i>	<i>ZRSR2</i>

**Table S7: Variant allele frequencies at diagnosis, C6D29, C12D29 and Progression**

Patient ID	Variant	VAF			
		Diagnosis	C6D29	Progression	C12D29
P01	IDH2_p.Arg140Trp	0	0		0.088
	ASXL1_p.Glu635fs	0.1493	0.1232		0.1714
	RUNX1_p.His105Gln	0.3597	0.191		0.3904
	SRSF2_p.Pro95His	0.3755	0.2407		0.3571
	STAG2_p.Ser843fs	0.6728	0.3191		0.7651
P02	STAG2_p.Ile920fs	0.0625	0.3147	0.1698	
	NRAS_p.Gly12Asp	0.2909	0.3776	0.3013	
	TET2_p.Arg1235Gln	0.3822	0.3669	0.323	
	ASXL1_p.Leu823fs	0.3952	0.4062	0.3964	
	PDGFRA_p.Gln722Glu	0.4703	0.3973	0.4828	
	SRSF2_p.Pro95Leu	0.4772	0.4746	0.3574	
	STAG2_p.Leu609fs	0.6821	0.4233	0.3547	
P03	TP53_p.Pro177His	0.248	0.0606		0.0632
	DNAJC21_p.Lys330Gln	0.4502	0.4566		0.426
P04	WT1_p.Thr455fs	0.2944	0		0.3361
	TET2_p.Gln1410*	0.3591	0.1382		0.418
	ASXL1_p.Ile395fs	0.3702	0.1975		0.4431
	TET2_p.Gln1701fs	0.451	0		0.4813
	CSF3R_p.His599Asn	0.4541	0.4661		0.5
	EZH2_p.Thr592fs	0.8202	0		0.8577
	SMC1A_p.Arg711Trp	0.8458	0.2163		0.9336
P05	RUNX1_p.Leu98fs	0.3684	0.136		0.2278
	TET2_p.Arg1237*	0.4153	0.1829		0.2236
	KIT_p.Ala755Val	0.4615	0.4545		0.417
	IKZF1_p.Thr96Met	0.49	0.4377		0.4758
	TET2_.	0.5123	0.304		0.3731
	RTEL1_p.Pro315Arg	0.5369	0.5074		0.5409
	SRSF2_p.Pro95His	0.5398	0.3247		0.322
P06	ETV6_p.Phe368Leu	0			0.1298
	SETBP1_p.Asp868Asn	0			0.135
	TP53_p.His179Gln	0.0532			0.1667
	U2AF1_p.Gln157Pro	0.0778			0.1976
	DNMT3A_p.Arg882Cys	0.1033			0.1422
P07	ASXL1_p.Arg620fs	0.2607	0.2521		0
	KRAS_p.Lys178del	0.4186	0.4173		0.5038
	RUNX1_.	0.426	0.3396		0
	SRSF2_p.Pro95His	0.4742	0.3248		0
	TET2_p.Glu1199fs	0.6576	0.5801		0
	STAG2_p.Arg259*	0.6867	0.6415		0

Patient ID	Variant	VAF			
		Diagnosis	C6D29	Progression	C12D29
P08	DNMT3A_p.Arg13Cys	0	0.2918	0.1526	
	RUNX1_p.Arg201Gln	0.2883	0.3956	0.1801	
	TET2_p.Lys1329Asn	0.3036	0.3846	0.1901	
	BCOR_p.Glu401fs	0.3051	0.0808	0	
	SRSF2_p.Pro95Arg	0.3319	0.4062	0.2213	
	WT1_p.Ala282Val	0.3361	0.4578	0.2073	
	DNMT3A_p.Met548Thr	0.3577	0.4556	0.352	
	TET2_p.Gln785fs	0.3593	0.3523	0.2521	
	TET2_p.Ser1224Arg	0.413	0.3802	0.4177	
P09	PARN_.	0	0.2692		
	ZRSR2_p.Ser40*	0.0644	0.064		
	PHF6_p.Gly10fs	0.0704	0		
P10	DDX41_p.Gly548Asp	0.0669	0.0923		0
	DDX41_p.Val463del	0.2581	0.2656		0.2151
P11	RUNX1_p.Arg427fs	0	0		0.1688
	IDH2_p.Arg140Gln	0.457	0.1958		0.1519
	SRSF2_p.Pro95His	0.4804	0.2155		0.2028
	RTEL1_p.Ala73Ser	0.5153	0.4861		0.5176
P12	ZRSR2_p.Glu133Lys	0.2258	0		0
	TET2_.	0.411	0.3034		0.3866
	TET2_p.Asn834fs	0.4206	0.207		0.3423
	PIK3CD_p.Glu646Lys	0.4725	0.4236		0.5127
	ZRSR2_p.Glu133fs	0.8544	0.1368		0.2143
P13	SF3B1_p.Lys700Glu	0.0657	0		0
	TP53_p.Pro151Ser	0.112	0.1667		0.1776
	TERT_p.Ala184Thr	0.4554	0.4466		0.4883
P14	STAG2_.	0.0761	0	0	
	GATA2_p.Gly320Asp	0.1202	0	0	
	RUNX1_p.Tyr287*	0.1392	0	0	
	SF3B1_p.Lys700Glu	0.4293	0	0.1296	
	ASXL1_p.Ala1172Thr	0.4803	0.5	0.4808	
	BCORL1_p.Arg1333Lys	0.5278	0.5541	0.5129	
P15	EZH2_p.Arg658Thr	0.0529	0.0513		
	DDX41_p.Arg543His	0.1362	0.0563		
P16	RUNX1_p.His242Arg	0.0753	0.0737		
	DDX41_p.Glu286Lys	0.2658	0.3307		
	TET2_p.Gln1653*	0.4449	0.4649		
	RUNX1_p.His242fs	0.5127	0.5769		
	CBL_p.Cys381Ser	0.7123	0.7903		
	ATM_p.Pro1374Leu	0.7565	0.7897		
	KMT2A_p.Met2783Ile	0.845	0.8007		
P17	ATM_p.Pro960His	0.3538	0.3926	0.4292	

Patient ID	Variant	VAF			
		Diagnosis	C6D29	Progression	C12D29
P18	ABL1_p.Ser554Cys	0	0	0.344	
	WT1_p.Pro136Arg	0	0	0.22	
	TP53_p.Cys238Tyr	0.3562	0	0.3761	
	TP53_p.Ser106Arg	0.4032	0	0.3867	
P19	TET2_p.Ile1370fs	0.2973	0.0874		
	KRAS_p.Gly12Arg	0.3765	0		
	TET2_p.Gly1309Val	0.4922	0.176		
	SRSF2_p.Pro95His	0.5424	0.2227		
P20	RAD21_p.Glu399fs	0.3525			
	TET2_.	0.4352			
	TET2_p.Gln984*	0.4453			
	EZH2_p.Gly628Arg	0.6437			
P21	TP53_p.Pro301fs	0.1799	0.2402		
	TP53_p.Arg273His	0.2479	0.3686		
	STIM1_p.Lys672Arg	0.5	0.5583		
	BRCA2_p.Lys115Glu	0.5083	0.4818		
	RUNX1_p.Pro245Leu	0.5849	0.6727		
P22	IDH2_p.Arg172Lys	0.403	0.4767		
P24	TP53_p.Pro151Ser	0.2209	0.2177		
P25	STAG2_p.Phe466fs	0.1038	0.0728		
	STAG2_p.Ser471Asn	0.1152	0.0876		
	RUNX1_p.Tyr377*	0.1602	0.1752		
	EZH2_p.Glu211fs	0.3367	0.4128		
	RUNX1_.	0.4115	0.4191		
	EZH2_p.Leu674Ser	0.4599	0.4256		
	DAXX_p.Pro540Leu	0.5184	0.4898		
P27	TET2_p.Ile1918Asn	0.453			
	DNMT3A_.	0.457			
	TET2_p.Thr1916fs	0.4956			
	KMT2A_p.Val2596Ala	0.5242			
	PRKD3_.	0.6			
	TP53_p.Arg273His	0.9437			
P28	RUNX1_p.Arg166Gln	0.1286			
	DNMT3A_p.Leu723Pro	0.212			
	IDH2_p.Arg172Lys	0.2816			
	DNMT3A_p.Phe734Ile	0.2886			
	GNAS_p.Pro96Ala	0.4894			
	GATA1_p.Gly89Glu	0.5272			
P35	SRSF2_.	0.0674			
	DNMT3A_p.Lys343fs	0.3158			
	NPM1_p.Pro191Ser	0.4051			
	TP53_.	0.4313			

Patient ID	Variant	VAF			
		Diagnosis	C6D29	Progression	C12D29
P38	MED12_p.Leu10Gln	0.0704			
	RUNX1_.	0.2924			
	SRSF2_p.Arg94dup	0.4352			
	IDH2_p.Arg140Gln	0.4684			
	PDGFRA_p.Thr157Ala	0.486			
	PPM1D_p.Pro500Arg	0.508			